STEINMETZ MICHAEL

Form 4

March 18, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

30(h) of the Investment Company Act of 1940

OMB Number:

3235-0287 January 31,

Expires:

OMB APPROVAL

2005

0.5

Estimated average

5 D L (* 1 * CD - (* D - () (

burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue.

1(b).

(Print or Type Responses)

1 Name and Address of Departing De

See Instruction

MPM BIOVENTURES II QP LP			Symbol AVEO	2. Issuer Name and Ticker or Trading Symbol AVEO PHARMACEUTICALS INC [AVEO]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
					3. Date of Earliest Transaction (Month/Day/Year) 03/17/2010				Director 10% Owner Officer (give titleX Other (specify below) Former 10% Stockholder			
	BOSTON, I	(Street) MA 02116			endment, D onth/Day/Yea	ate Original ur)		- -	5. Individual or Jo Applicable Line) Form filed by O X_ Form filed by M Person	ne Reporting Per	rson	
	(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative Sec	urities		red, Disposed of	, or Beneficial	ly Owned	
	1.Title of Security (Instr. 3)	2. Transaction De (Month/Day/Yea	ar) Execution		3. Transactic Code (Instr. 8)	4. Securities a corr Disposed of (Instr. 3, 4 an	of (D)	ed (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Common Stock	03/17/2010			C C	1,037,036 (3)	A	(2)	1,037,036	I	See Footnote (6)	
	Common Stock	03/17/2010			С	977,850 (4)	A	<u>(2)</u>	2,014,886	I	See Footnote (7)	
	Common Stock	03/17/2010			C	194,075 (5)	A	(2)	2,208,961	I	See Footnote	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series A Convertible Preferred Stock	(2)	03/17/2010		C		4,148,148	<u>(1)</u>	<u>(1)</u>	Common Stock	1,037,
Series B Convertible Preferred Stock	(2)	03/17/2010		С		3,911,405	<u>(1)</u>	<u>(1)</u>	Common Stock	977,8 (4)
Series D Convertible Preferred Stock	<u>(2)</u>	03/17/2010		С		776,307	<u>(1)</u>	<u>(1)</u>	Common Stock	194,0 (5)

Reporting Owners

			Relations	hips
Reporting Owner Name / Address		10% Owner	Officer	Other
MPM BIOVENTURES II QP LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116				Former 10% Stockholder
MPM BIOVENTURES II LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116				Former 10% Stockholder
MPM ASSET MANAGEMENT II LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR				Former 10% Stockholder

Reporting Owners 2

BOSTON. MA 02116

MPM ASSET MANAGEMENT INVESTORS 2002 BVII LLC

C/O MPM ASSET MANAGEMENT

200 CLARENDON STREET, 54TH FLOOR

Stockholder

BOSTON, MA 02116

MPM BIOVENTURES GMBH & CO PARALLEL

BETEILIGUNGS KG
C/O MPM ASSET MANAGEMENT
200 CLARENDON STREET, 54TH FLOOR
Former 10%
Stockholder

BOSTON, MA 02116

MPM ASSET MANAGEMENT II LP

C/O MPM ASSET MANAGEMENT

200 CLARENDON STREET, 54TH FLOOR

Stockholder

BOSTON, MA 02116

EVNIN LUKE

C/O MPM ASSET MANAGEMENT Former 10% 200 CLARENDON STREET, 54TH FLOOR Stockholder

BOSTON, MA 02116

GADICKE ANSBERT

C/O MPM ASSET MANAGEMENT Former 10% 200 CLARENDON STREET, 54TH FLOOR Stockholder

BOSTON, MA 02116

STEINMETZ MICHAEL

C/O MPM ASSET MANAGEMENT Former 10% 200 CLARENDON STREET, 54TH FLOOR Stockholder

BOSTON, MA 02116

WHEELER KURT

C/O MPM ASSET MANAGEMENT Former 10% 200 CLARENDON STREET, 54TH FLOOR Stockholder

BOSTON, MA 02116

Signatures

By Luke Evnin, manager of MPM Asset Management II LLC, the general partner of MPM Asset Management II, L.P., the general partner of MPM BioVentures II-QP, L.P. /s/ Luke Evnin 03/17/2010

**Signature of Reporting Person Date

03/17/2010

03/17/2010

Date

03/17/2010

By Luke Evnin, manager of MPM Asset Management II LLC, the general partner of MPM Asset Management II, L.P., the general partner of MPM BioVentures II, L.P. /s/ Luke Evnin

**Signature of Reporting Person Date

By Luke Evnin, manager of MPM Asset Management II LLC /s/ Luke Evnin

**Signature of Reporting Person

By Luke Evnin, manager of MPM Asset Management Investors 2002 BVII LLC /s/ Luke Evnin

**Signature of Reporting Person Date

Signatures 3

By Luke Evnin, manager of MPM	Asset Management II LLC, the general partner of MPM				
Asset Management II, L.P., the special limited partner of MPM BioVentures GmbH & Co.					
Parallel-Beteiligungs KG /s/ Luke	Evnin	03/17/2010			
	**Signature of Reporting Person	Date			
·	Asset Management II LLC, the general partner of MPM	02/17/2010			
Asset Management II, L.P. /s/ Luk	e Evnin	03/17/2010			
	**Signature of Reporting Person	Date			
/s/ Luke Evnin					
75/ Luke Eviiiii		03/17/2010			
	**Signature of Reporting Person	Date			
/s/ Ansbert Gadicke		03/17/2010			
	**Signature of Reporting Person	Date			
/s/ Michael Steinmetz		03/17/2010			
	**Signature of Reporting Person	Date			
/s/ Kurt Wheeler		03/17/2010			

	**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are preferred stock of the Issuer and do not have an expiration date. These securities automatically converted into shares of common stock upon the closing of the Issuer's initial public offering.
- Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series D Convertible Preferred Stock (2) automatically converted into shares of Common Stock on a 0.25 for 1 basis immediately upon the closing of the Issuer's initial public offering.
 - The shares, on a post-conversion basis, are held as follows: 701,037 by MPM BioVentures II-QP, L.P. ("BV II QP"), 77,259 by MPM BioVentures II, L.P. ("BV II"), 11,926 by MPM Asset Management Investors 2002 BVII LLC ("AM 2002") and 246,814 by MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG ("BV KG"). MPM Asset Management II, L.P. ("AM II GP") and MPM Asset
- (3) Management II LLC ("AM II LLC") are the direct and indirect general partners of BV II QP, BV II and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Michael Steinmetz and Kurt Wheeler are the investment managers of AM II LLC and AM 2002. Each member of the group disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- The shares, on a post-conversion basis, are held as follows: 661,027 by BV II QP, 72,850 by BV II, 11,245 by AM 2002 and 232,728 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- The shares, on a post-conversion basis, are held as follows: 131,196 by BV II QP, 14,458 by BV II, 2,231 by AM 2002 and 46,190 by BV (5) KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- (6) The shares are held as follows: 701,037 by BV II QP, 77,259 by BV II, 11,926 by AM 2002 and 246,814 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- (7) The shares are held as follows: 1,362,064 by BV II QP, 150,109 by BV II, 23,171 by AM 2002 and 479,542 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
- (8) The shares are held as follows: 1,493,260 by BV II QP, 164,567 by BV II, 25,402 by AM 2002 and 525,732 by BV KG. Each member of the group disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.